Lv11
50 积分 2024-09-18 加入
High time for risk-adapted treatment in mantle cell lymphoma
1个月前
已完结
Simplified Calculation of Body-Surface Area
1个月前
已完结
Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy
1个月前
已完结
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
1个月前
已完结
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study
1个月前
已完结
596 | THE BURDEN OF RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA IN ENGLAND: A RETROSPECTIVE ANALYSIS OF REAL‐WORD TREATMENT PATTERNS AND OUTCOMES
1个月前
已关闭
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
1个月前
已完结
Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy
1个月前
已完结
Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era
1个月前
已完结
Advances in the Pathogenesis, Diagnosis, Treatment, and Prognosis of Marginal Zone Lymphoma
1个月前
已完结
皖公网安备34019202002308
